Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-NOVUM 7/14-28 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women ≥15 years of age who have no known contraindications and have achieved menarche,Off-label: menstrual cycle regulation, dysmenorrhea, endometriosis-associated pain
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet daily for 28 days; each tablet contains norethindrone 0.5 mg and ethinyl estradiol 0.035 mg (days 1-7), norethindrone 0.75 mg and ethinyl estradiol 0.035 mg (days 8-14), norethindrone 1 mg and ethinyl estradiol 0.035 mg (days 15-21), and placebo (days 22-28). Take at same time each day.
400 mg orally once daily with food.
Ethinyl estradiol: ~13-27 h (mean 17 h); Norethindrone: ~5-14 h (mean 8 h). Clinical context: steady-state achieved after ~5 days; half-life supports daily dosing.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Ethinyl estradiol: primarily metabolized via CYP3A4, undergoes first-pass metabolism and enterohepatic circulation. Norethindrone: reduced to metabolites, conjugated (glucuronidation and sulfation), and excreted in urine and feces.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal: ~50-60% (metabolites); biliary/fecal: ~30-40% (metabolites); unchanged drug <1% in urine.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Ethinyl estradiol: 97-98% bound to serum albumin; Norethindrone: 97-99% bound to albumin (major) and SHBG (minor).
98% bound to albumin
Ethinyl estradiol: 2.3-4.2 L/kg (mean 3.5 L/kg); Norethindrone: 2.5-5.0 L/kg (mean 3.8 L/kg). Clinical meaning: extensive distribution into tissues, including reproductive organs.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: Ethinyl estradiol ~40-48% (first-pass metabolism); Norethindrone ~50-70% (first-pass metabolism). Food may slightly increase bioavailability.
Oral: 85-90%; IM: 95-100%
No specific dose adjustment recommended in published literature; however, use with caution in patients with severe renal impairment (e GFR <30 m L/min) due to potential fluid retention and electrolyte disturbances. No data for specific GFR-based modifications.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) or hepatic tumors. For Child-Pugh class A or B, use with caution; no specific dose adjustment guidelines exist. Discontinue if jaundice or signs of hepatic dysfunction develop.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults: one tablet daily for 28 days. Use only after appropriate evaluation and counseling.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for use in postmenopausal women. Elderly-specific dosing not applicable.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular events. Women over 35 who smoke should not use this product.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Increased risk of thromboembolic disorders (DVT, PE, stroke, MI),Cigarette smoking increases cardiovascular risk,Increased risk of cervical cancer (HPV-related),Hepatic neoplasia (benign/malignant) associated with long-term use,Exacerbation of migraine,Depression,Gallbladder disease,Impaired glucose tolerance,Elevated blood pressure,Hereditary angioedema
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Known or suspected pregnancy,Current or past history of thromboembolic disorders (e.g., DVT, PE),Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Active liver disease or benign/malignant liver tumors,Undiagnosed abnormal genital bleeding,Hypersensitivity to any component,Age >35 and smoking cigarettes,Uncontrolled hypertension,Diabetes with vascular involvement,Migraine with focal aura at any age,Major surgery with prolonged immobilization
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
Grapefruit juice may increase ethinyl estradiol levels and risk of adverse effects; consider avoiding. No other significant food interactions.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
First trimester: Post-marketing studies have not shown an increased risk of birth defects with combined oral contraceptives. However, inadvertent use during early pregnancy is not associated with teratogenicity. Second and third trimesters: Use is contraindicated due to potential adverse effects on fetal development, including estrogenic effects on female fetuses and androgenic effects on male fetuses. There is a risk of fetal genital abnormalities if exposed in utero, though absolute risk is low. Overall, category X designation for use during pregnancy.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Combined oral contraceptives, including Ortho-Novum, are generally not recommended during breastfeeding, especially in the early postpartum period, due to estrogen-induced reduction in milk production and quality. Small amounts of ethinylestradiol and norethindrone are excreted in breast milk. M/P ratio for ethinylestradiol is approximately 0.15–0.3; for norethindrone, approximately 0.5–1.2. Progestin-only methods are preferred. Use only when no alternative and with caution.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Ortho-Novum is contraindicated in pregnancy. No dose adjustments are recommended because use during pregnancy is not indicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) would theoretically require dose modifications, but since the drug is contraindicated, no adjustment is applicable.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
ORTHO-NOVUM 7/14-28 is a triphasic oral contraceptive with variable doses of norethindrone and ethinyl estradiol. Bleeding irregularities are common, especially in the first few cycles; reassure patients if pregnancy is ruled out. Missed pills increase risk of breakthrough ovulation; refer to package instructions for missed doses. Concomitant use of CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) may reduce contraceptive efficacy.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill daily at the same time, starting on the first Sunday after your period begins.,Use backup contraception (e.g., condoms) for the first 7 days of the first cycle.,If you miss a pill, follow the specific instructions in the package insert based on how many you missed and the week of the cycle.,Common side effects include nausea, breast tenderness, and spotting; these often improve after 2-3 cycles.,Smoking increases the risk of serious cardiovascular side effects, especially if you are over 35 years old.,This medication does not protect against HIV or other sexually transmitted infections.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORTHO-NOVUM 7/14-28 vs ADQUEY, answered by our medical review team.
ORTHO-NOVUM 7/14-28 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORTHO-NOVUM 7/14-28 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORTHO-NOVUM 7/14-28 is: One tablet daily for 28 days; each tablet contains norethindrone 0.5 mg and ethinyl estradiol 0.035 mg (days 1-7), norethindrone 0.75 mg and ethinyl estradiol 0.035 mg (days 8-14), norethindrone 1 mg and ethinyl estradiol 0.035 mg (days 15-21), and placebo (days 22-28). Take at same time each day.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORTHO-NOVUM 7/14-28 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORTHO-NOVUM 7/14-28 is classified as Category C. First trimester: Post-marketing studies have not shown an increased risk of birth defects with combined oral contraceptives. However, inadvertent use during early pregnancy is not . ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.